Review Article
Research progress of radiolabeled FAPIs in the tumor targeted diagnosis and therapy
Yili Xiang, Zhongbao Ruan, Jun Zhang, Li Zhu
Published 2021-11-25
Cite as Chin J Nucl Med Mol Imaging, 2021, 41(11): 683-688. DOI: 10.3760/cma.j.cn321828-20200421-00162
Abstract
Cancer-associated fibroblasts (CAFs) are essential parts of tumor stroma. Fibroblast activation protein (FAP), overexpressed in CAFs, is closely related to tumor growth, invasion, metastasis, immunosuppression and prognosis, which is a vital target for tumor targeted diagnosis and therapy. In recent years, a variety of new radiolabeled quinoline-based FAP inhibitors (FAPIs) have been used for tumor targeted diagnostic and therapeutic research. A number of studies have confirmed that radiolabeled FAPIs plays an important role in tumor diagnosis, staging and treatment, which have a good clinical application prospect. This review summarizes the research status of radiolabeled FAPIs and discusses their potential in the accurate diagnosis and therapy of tumors.
Key words:
Quinolines; Isotope labeling; Neoplasms; Trends
Contributor Information
Yili Xiang
Department of Nuclear Medicine, Taizhou People′s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China
Zhongbao Ruan
Department of Cardiology, Taizhou People′s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China
Jun Zhang
Department of Nuclear Medicine, Taizhou People′s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China
Li Zhu
Department of Cardiology, Taizhou People′s Hospital Affiliated to Nanjing University of Chinese Medicine, Taizhou 225300, China